Emerging evidence suggests that CTNNB1 mutations may correlate with poor prognosis and therapeutic resistance in lung adenocarcinoma.[10–12] Furthermore, the tumor suppressor gene APC, whose loss of function has been associated with immune checkpoint inhibitor resistance in NSCLC,[13] may also modulate the efficacy of TKI in ROS1-positive NSCLC. The gene discussed is ROS1; the disease is non-small cell lung carcinoma.